Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryAug202013	Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to Read All »	View HTML Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering 11.2 KB
Toggle SummaryApr222013	Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the presentation of preclinical data from its WNT7a protein analog program for the treatment of muscular dystrophy at the Read All »	View HTML Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference 14 KB
Toggle SummaryFeb252013	Fate Therapeutics to Present at Cowen & Co. 33rd Annual Health Care Conference Fate Therapeutics to Present at Cowen & Co. 33rd Annual Health Care Conference San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today that Christian Weyer, M.D., M.A.S., President Read All »	View HTML Fate Therapeutics to Present at Cowen & Co. 33rd Annual Health Care Conference 10 KB
Toggle SummaryFeb072013	Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference SAN DIEGO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will be presenting a company overview Read All »	View HTML Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference 9.8 KB
Toggle SummaryDec042012	Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today several advancements in its goal Read All »	View HTML Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics 11.2 KB
Toggle SummaryNov272012	Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a Read All »	View HTML Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies 12 KB
Toggle SummaryOct152012	Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer San Diego, CA – Fate Therapeutics, Inc. announced today that Christian Weyer, M.D., M.A.S. has been appointed President and Chief Executive Officer and elected to the Company’s Board of Directors, Read All »	View HTML Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer 11.3 KB
Toggle SummaryJun112012	Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications San Diego, CA – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. Read All »	View HTML Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications 11.3 KB
Toggle SummaryDec142011	Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman and Interim CEO San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May Read All »	View HTML Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO 188.1 KB
Toggle SummaryDec132011	Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All »	View HTML Fate Therapeutics announces promising data from Phase 1B study of ProHema at the 2011 American Society of Hematology Annual Conference 15.3 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.